These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17341629)

  • 1. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
    Savickiene J; Treigyte G; Borutinskaite V; Navakauskiene R; Magnusson KE
    Ann N Y Acad Sci; 2006 Dec; 1091():368-84. PubMed ID: 17341629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.
    Savickiene J; Borutinskaite VV; Treigyte G; Magnusson KE; Navakauskiene R
    Eur J Pharmacol; 2006 Nov; 549(1-3):9-18. PubMed ID: 16978604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
    J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
    Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
    Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
    Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
    Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
    Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H
    Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C/EBPα and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.
    Savickiene J; Treigyte G; Vistartaite G; Tunaitis V; Magnusson KE; Navakauskiene R
    Differentiation; 2011 Jan; 81(1):57-67. PubMed ID: 20864248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic differentiation of human promyelocytic leukemia HL-60 cells.
    Merzvinskyte R; Treigyte G; Savickiene J; Magnusson KE; Navakauskiene R
    Ann N Y Acad Sci; 2006 Dec; 1091():356-67. PubMed ID: 17341628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
    Vinodhkumar R; Song YS; Devaki T
    Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
    Hoshino I; Matsubara H; Akutsu Y; Nishimori T; Yoneyama Y; Murakami K; Komatsu A; Sakata H; Matsushita K; Ochiai T
    Oncol Rep; 2007 Sep; 18(3):585-92. PubMed ID: 17671705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
    Kobayashi Y; Ohtsuki M; Murakami T; Kobayashi T; Sutheesophon K; Kitayama H; Kano Y; Kusano E; Nakagawa H; Furukawa Y
    Oncogene; 2006 Jan; 25(4):512-24. PubMed ID: 16186804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.
    Sawa H; Murakami H; Kumagai M; Nakasato M; Yamauchi S; Matsuyama N; Tamura Y; Satone A; Ide W; Hashimoto I; Kamada H
    Acta Neuropathol; 2004 Jun; 107(6):523-31. PubMed ID: 15024582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis.
    Zhang Y; Adachi M; Kawamura R; Imai K
    Cell Death Differ; 2006 Jan; 13(1):129-40. PubMed ID: 15947789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
    Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
    Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells.
    Borutinskaite VV; Navakauskiene R; Magnusson KE
    Ann N Y Acad Sci; 2006 Dec; 1091():346-55. PubMed ID: 17341627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
    Adachi M; Zhang Y; Zhao X; Minami T; Kawamura R; Hinoda Y; Imai K
    Clin Cancer Res; 2004 Jun; 10(11):3853-62. PubMed ID: 15173094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
    Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
    Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
    Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
    Matsubara H; Watanabe M; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Kamitsuji Y; Watanabe K; Nishijo K; Toguchida J; Nakahata T; Adachi S
    J Pharmacol Exp Ther; 2009 Mar; 328(3):839-48. PubMed ID: 19073909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sp1 and NF-kappaB transcription factor activity in the regulation of the p21 and FasL promoters during promyelocytic leukemia cell monocytic differentiation and its associated apoptosis.
    Savickiene J; Treigyte G; Pivoriunas A; Navakauskiene R; Magnusson KE
    Ann N Y Acad Sci; 2004 Dec; 1030():569-77. PubMed ID: 15659839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.